Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Meril Life Sciences, an India-based medical device company founded in 2006, developed the Myval TAVR valve

Myval TAVR valve noninferior to similar devices from Medtronic, Edwards after 30 days

The balloon-expandable valve is already approved for use in India and Europe. New data presented at EuroPCR 2024 in Paris compared it to contemporary devices seen by many as the gold standard for TAVR care. 

cardiologist viewing heart data

Cardiologists examine how residual TR after transcatheter tricuspid valve repair impacts survival

Researchers tracked data from more than 600 patients, noting that heart teams may want to reconsider how they classify residual TR after treatment. 

4C Medical Technologies AltaValve

FDA grants breakthrough device designation to new TMVR device from 4C Medical

The supra-annular AltaValve System was designed to treat both primary and secondary mitral regurgitation. It is implanted via transseptal access and positioned above the native mitral valve.

Cardiologist Heart Doctor Tablet Technology

TAVR, SAVR linked to comparable long-term outcomes, new meta-analysis confirms

Researchers tracked data from more than 7,500 patients, sharing their findings at EuroPCR 2024 in Paris and in JSCAI.

Edwards Lifesciences Sapien 3 Ultra Resilia TAVR

Updated balloon-expandable TAVR valve from Edwards outperforming its predecessors

The fifth-generation valve is associated with improved hemodynamic data and a reduced rate of paravalvular leak, according to new research published in JACC: Cardiovascular Interventions and EuroIntervention.

doctor examines patient data on their tablet

Moderate aortic stenosis linked to heightened risk of death—should TAVR, surgery be considered?

Researchers tracked data from more than 400,000 patients for a new meta-analysis, presenting their findings in the Journal of the American Heart Association.

Interventional cardiologist James B. Hermiller, MD, is officially the new president of the Society for Cardiovascular Angiography & Interventions (SCAI).

SCAI president begins term on optimistic note: ‘Our field’s future is brighter than ever’

Interventional cardiologist James B. Hermiller, MD, officially assumed the position at the end of SCAI 2024 Scientific Sessions.

The DurAVR TAVR system from Anteris Technologies

New-look TAVR valve shows early promise in patients with severe AS

One-year data presented at SCAI's annual meeting suggest interventional cardiologists could soon have a new way to treat severe aortic stenosis.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Trimed Popup
Trimed Popup